Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective Inhibitors
{{output}}
Glycogen synthase kinase 3 (GSK3) remains a therapeutic target of interest for diverse clinical indications. However, one hurdle in the development of small molecule GSK3 inhibitors has been safety concerns related to pan-inhibition of both GSK3 paralogs, lead... ...
